JP2018522070A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018522070A5 JP2018522070A5 JP2018525507A JP2018525507A JP2018522070A5 JP 2018522070 A5 JP2018522070 A5 JP 2018522070A5 JP 2018525507 A JP2018525507 A JP 2018525507A JP 2018525507 A JP2018525507 A JP 2018525507A JP 2018522070 A5 JP2018522070 A5 JP 2018522070A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- cholesten
- composition according
- steroid
- cataract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 40
- 150000003431 steroids Chemical class 0.000 claims 10
- 208000002177 Cataract Diseases 0.000 claims 9
- 229910004727 OSO3H Inorganic materials 0.000 claims 5
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- CHGIKSSZNBCNDW-UHFFFAOYSA-N (3beta,5alpha)-4,4-Dimethylcholesta-8,24-dien-3-ol Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21 CHGIKSSZNBCNDW-UHFFFAOYSA-N 0.000 claims 3
- JQMQKOQOLPGBBE-ZNCJEFCDSA-N (3s,5s,8s,9s,10r,13r,14s,17r)-3-hydroxy-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-1,2,3,4,5,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-6-one Chemical compound C([C@@H]1C(=O)C2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CCCC(C)C)[C@@]2(C)CC1 JQMQKOQOLPGBBE-ZNCJEFCDSA-N 0.000 claims 3
- JQMQKOQOLPGBBE-UHFFFAOYSA-N 6-ketocholestanol Natural products C1C(=O)C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 JQMQKOQOLPGBBE-UHFFFAOYSA-N 0.000 claims 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims 3
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 claims 2
- 230000002776 aggregation Effects 0.000 claims 2
- 238000004220 aggregation Methods 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 239000001913 cellulose Substances 0.000 claims 2
- 229920002678 cellulose Polymers 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 230000006378 damage Effects 0.000 claims 2
- QBSJHOGDIUQWTH-UHFFFAOYSA-N dihydrolanosterol Natural products CC(C)CCCC(C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(C)(O)C(C)(C)C4CC3 QBSJHOGDIUQWTH-UHFFFAOYSA-N 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 230000003902 lesion Effects 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 229910021653 sulphate ion Inorganic materials 0.000 claims 2
- 238000011200 topical administration Methods 0.000 claims 2
- BQPPJGMMIYJVBR-UHFFFAOYSA-N (10S)-3c-Acetoxy-4.4.10r.13c.14t-pentamethyl-17c-((R)-1.5-dimethyl-hexen-(4)-yl)-(5tH)-Delta8-tetradecahydro-1H-cyclopenta[a]phenanthren Natural products CC12CCC(OC(C)=O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C BQPPJGMMIYJVBR-UHFFFAOYSA-N 0.000 claims 1
- MBZYKEVPFYHDOH-UHFFFAOYSA-N (10S)-3c-Hydroxy-4.4.10r.13t.14c-pentamethyl-17t-((R)-1.5-dimethyl-hexyl)-(5tH)-Delta8-tetradecahydro-1H-cyclopenta[a]phenanthren Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(C)CCCC(C)C)CCC21C MBZYKEVPFYHDOH-UHFFFAOYSA-N 0.000 claims 1
- FYHRJWMENCALJY-YSQMORBQSA-N (25R)-cholest-5-ene-3beta,26-diol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCC[C@H](CO)C)[C@@]1(C)CC2 FYHRJWMENCALJY-YSQMORBQSA-N 0.000 claims 1
- CHGIKSSZNBCNDW-LCHSQBAESA-N (3s,10s,13r,14r,17r)-4,4,10,13-tetramethyl-17-[(2r)-6-methylhept-5-en-2-yl]-1,2,3,5,6,7,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-ol Chemical compound C([C@@]12C)C[C@H](O)C(C)(C)C1CCC1=C2CC[C@]2(C)[C@@H]([C@@H](CCC=C(C)C)C)CC[C@H]21 CHGIKSSZNBCNDW-LCHSQBAESA-N 0.000 claims 1
- FYHRVINOXYETMN-LCHSQBAESA-N (3s,10s,13r,14r,17r)-4,4,10,13-tetramethyl-17-[(2r)-6-methylheptan-2-yl]-1,2,3,5,6,7,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-ol Chemical compound C([C@@]12C)C[C@H](O)C(C)(C)C1CCC1=C2CC[C@]2(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]21 FYHRVINOXYETMN-LCHSQBAESA-N 0.000 claims 1
- CHGIKSSZNBCNDW-QGBOJXOESA-N 14-demethyllanosterol Chemical compound C([C@@]12C)C[C@H](O)C(C)(C)[C@@H]1CCC1=C2CC[C@]2(C)[C@@H]([C@@H](CCC=C(C)C)C)CC[C@H]21 CHGIKSSZNBCNDW-QGBOJXOESA-N 0.000 claims 1
- XYTLYKGXLMKYMV-UHFFFAOYSA-N 14alpha-methylzymosterol Natural products CC12CCC(O)CC1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C XYTLYKGXLMKYMV-UHFFFAOYSA-N 0.000 claims 1
- MBZYKEVPFYHDOH-BQNIITSRSA-N 24,25-dihydrolanosterol Chemical compound C([C@@]12C)C[C@H](O)C(C)(C)[C@@H]1CCC1=C2CC[C@]2(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@]21C MBZYKEVPFYHDOH-BQNIITSRSA-N 0.000 claims 1
- DKISDYAXCJJSLZ-UHFFFAOYSA-N 26-Hydroxy-cholesterin Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCCC(CO)C)C1(C)CC2 DKISDYAXCJJSLZ-UHFFFAOYSA-N 0.000 claims 1
- FPTJELQXIUUCEY-UHFFFAOYSA-N 3beta-Hydroxy-lanostan Natural products C1CC2C(C)(C)C(O)CCC2(C)C2C1C1(C)CCC(C(C)CCCC(C)C)C1(C)CC2 FPTJELQXIUUCEY-UHFFFAOYSA-N 0.000 claims 1
- LFQXEZVYNCBVDO-PBJLWWPKSA-N 4,4-dimethyl-5alpha-cholesta-8,14,24-trien-3beta-ol Chemical compound C([C@@]12C)C[C@H](O)C(C)(C)[C@@H]1CCC1=C2CC[C@]2(C)[C@@H]([C@@H](CCC=C(C)C)C)CC=C21 LFQXEZVYNCBVDO-PBJLWWPKSA-N 0.000 claims 1
- IZVFFXVYBHFIHY-SKCNUYALSA-N 5alpha-cholest-7-en-3beta-ol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@H](C)CCCC(C)C)CC[C@H]33)C)C3=CC[C@H]21 IZVFFXVYBHFIHY-SKCNUYALSA-N 0.000 claims 1
- RUSSPKPUXDSHNC-DDPQNLDTSA-N 7-dehydrodesmosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@H](CCC=C(C)C)C)CC[C@H]33)C)C3=CC=C21 RUSSPKPUXDSHNC-DDPQNLDTSA-N 0.000 claims 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims 1
- 102000014824 Crystallins Human genes 0.000 claims 1
- 108010064003 Crystallins Proteins 0.000 claims 1
- UCTLRSWJYQTBFZ-UHFFFAOYSA-N Dehydrocholesterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCCC(C)C)CCC33)C)C3=CC=C21 UCTLRSWJYQTBFZ-UHFFFAOYSA-N 0.000 claims 1
- BDCFUHIWJODVNG-UHFFFAOYSA-N Desmosterol Natural products C1C=C2CC(O)C=CC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 BDCFUHIWJODVNG-UHFFFAOYSA-N 0.000 claims 1
- BKLIAINBCQPSOV-UHFFFAOYSA-N Gluanol Natural products CC(C)CC=CC(C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(O)C(C)(C)C4CC3 BKLIAINBCQPSOV-UHFFFAOYSA-N 0.000 claims 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims 1
- LOPKHWOTGJIQLC-UHFFFAOYSA-N Lanosterol Natural products CC(CCC=C(C)C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(C)(O)C(C)(C)C4CC3 LOPKHWOTGJIQLC-UHFFFAOYSA-N 0.000 claims 1
- CAHGCLMLTWQZNJ-UHFFFAOYSA-N Nerifoliol Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C CAHGCLMLTWQZNJ-UHFFFAOYSA-N 0.000 claims 1
- 208000022873 Ocular disease Diseases 0.000 claims 1
- 206010030043 Ocular hypertension Diseases 0.000 claims 1
- 208000021957 Ocular injury Diseases 0.000 claims 1
- 206010030348 Open-Angle Glaucoma Diseases 0.000 claims 1
- 235000019445 benzyl alcohol Nutrition 0.000 claims 1
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims 1
- DTGDZMYNKLTSKC-HKQCOZBKSA-N cholest-5-ene Chemical compound C1C=C2CCCC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 DTGDZMYNKLTSKC-HKQCOZBKSA-N 0.000 claims 1
- DTGDZMYNKLTSKC-UHFFFAOYSA-N cholest-5-ene Natural products C1C=C2CCCCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 DTGDZMYNKLTSKC-UHFFFAOYSA-N 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- -1 cholesteryl ester Chemical class 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- AVSXSVCZWQODGV-DPAQBDIFSA-N desmosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@@H](CCC=C(C)C)C)[C@@]1(C)CC2 AVSXSVCZWQODGV-DPAQBDIFSA-N 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- VFNGKCDDZUSWLR-UHFFFAOYSA-L disulfate(2-) Chemical compound [O-]S(=O)(=O)OS([O-])(=O)=O VFNGKCDDZUSWLR-UHFFFAOYSA-L 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- CAHGCLMLTWQZNJ-RGEKOYMOSA-N lanosterol Chemical compound C([C@]12C)C[C@@H](O)C(C)(C)[C@H]1CCC1=C2CC[C@]2(C)[C@H]([C@H](CCC=C(C)C)C)CC[C@@]21C CAHGCLMLTWQZNJ-RGEKOYMOSA-N 0.000 claims 1
- 229940058690 lanosterol Drugs 0.000 claims 1
- 239000000314 lubricant Substances 0.000 claims 1
- 239000002105 nanoparticle Substances 0.000 claims 1
- 208000013441 ocular lesion Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229940124531 pharmaceutical excipient Drugs 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 230000002335 preservative effect Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 201000006366 primary open angle glaucoma Diseases 0.000 claims 1
- 230000004845 protein aggregation Effects 0.000 claims 1
- 230000002441 reversible effect Effects 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims 1
- 230000003442 weekly effect Effects 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562197477P | 2015-07-27 | 2015-07-27 | |
| US62/197,477 | 2015-07-27 | ||
| US201562202518P | 2015-08-07 | 2015-08-07 | |
| US62/202,518 | 2015-08-07 | ||
| US201562252120P | 2015-11-06 | 2015-11-06 | |
| US62/252,120 | 2015-11-06 | ||
| US201662295267P | 2016-02-15 | 2016-02-15 | |
| US62/295,267 | 2016-02-15 | ||
| PCT/US2016/044337 WO2017019808A1 (en) | 2015-07-27 | 2016-07-27 | Compositions for the treatment of cataracts |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018522070A JP2018522070A (ja) | 2018-08-09 |
| JP2018522070A5 true JP2018522070A5 (https=) | 2019-06-20 |
Family
ID=56616065
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018525507A Pending JP2018522070A (ja) | 2015-07-27 | 2016-07-27 | 白内障の処置用組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US10398709B2 (https=) |
| EP (1) | EP3328389A1 (https=) |
| JP (1) | JP2018522070A (https=) |
| CN (1) | CN108472303A (https=) |
| AU (1) | AU2016298951B2 (https=) |
| CA (1) | CA2993196A1 (https=) |
| WO (1) | WO2017019808A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006047022A1 (en) | 2004-10-25 | 2006-05-04 | Virginia Commonwealth University | Nuclear sulfated oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and atherosclerosis |
| PL3639828T3 (pl) | 2013-12-24 | 2022-05-02 | Virginia Commonwealth University | Zastosowanie utlenowanych siarczanów cholesterolu (ocs) w leczeniu ostrej niewydolności wątroby |
| US20180250313A1 (en) * | 2015-09-08 | 2018-09-06 | Viewpoint Therapeutics, Inc. | Compounds and formulations for treating ophthalmic diseases |
| EP3494125B1 (en) | 2016-08-02 | 2022-06-22 | Virginia Commonwealth University | Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25hc3s) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide |
| WO2019097434A1 (en) * | 2017-11-17 | 2019-05-23 | Mahmood Piraee | Combinations of lanosterol or 25-hydroxycholesterol including derivatives thereof useful in the treatment of lens disorders |
| EP3813794A4 (en) * | 2018-06-27 | 2022-07-13 | Cellix Bio Private Limited | COMPOSITIONS AND METHODS OF TREATMENT EYE DISEASES |
| EP3955916A4 (en) * | 2019-04-19 | 2023-01-25 | Buck Institute for Research on Aging | 25-HYDROXYCHOLESTEROL (25HC), A CRYAB AGGREGATION INHIBITOR, IS A NEW SENOLYTIC |
| MX2021009520A (es) | 2021-08-06 | 2023-02-07 | Foodvica S A De C V | Composicion oftalmica para el tratamiento de trastornos visuales. |
| JP7784526B2 (ja) * | 2021-08-18 | 2025-12-11 | コアンチョウ オキュサン オフサルミック バイオテクノロジー カンパニー リミテッド | ステロイド化合物の、飛蚊症を予防及び／又は治療する薬物の調製における応用 |
| JP7784525B2 (ja) * | 2021-08-18 | 2025-12-11 | コアンチョウ オキュサン オフサルミック バイオテクノロジー カンパニー リミテッド | 薬物組成物、その調製方法及び応用 |
| CN115737654B (zh) | 2021-09-03 | 2025-11-21 | 成都瑞沐生物医药科技有限公司 | 一种滴眼给药预防和/或治疗白内障的眼用制剂 |
| KR20240134913A (ko) | 2022-01-21 | 2024-09-10 | 센주 유에스에이, 인코포레이티드 | 수성 액제 |
| KR20250134186A (ko) * | 2022-12-23 | 2025-09-09 | 듀렉트 코퍼레이션 | 25-히드록시-콜레스트-5-엔-3-술페이트 콜린, 이의 제형 및 이의 제조 방법, 및 의학적 용도 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2798053A (en) | 1952-09-03 | 1957-07-02 | Goodrich Co B F | Carboxylic polymers |
| US4192827A (en) | 1974-06-27 | 1980-03-11 | Ciba-Geigy Corporation | Water-insoluble hydrophilic copolymers |
| US4136250A (en) | 1977-07-20 | 1979-01-23 | Ciba-Geigy Corporation | Polysiloxane hydrogels |
| US4548990A (en) | 1983-08-15 | 1985-10-22 | Ciba-Geigy Corporation | Crosslinked, porous polymers for controlled drug delivery |
| US5192535A (en) | 1988-02-08 | 1993-03-09 | Insite Vision Incorporated | Ophthalmic suspensions |
| US20020132758A1 (en) | 2001-01-18 | 2002-09-19 | Shell John W. | Method for identifying compounds to treat medical pathologies associated with molecular crystallization |
| JP2005511713A (ja) * | 2001-12-07 | 2005-04-28 | ザ・リージェンツ・オブ・ザ・ユニバーシティー・オブ・カリフォルニア | 加齢性黄斑変性についての処置 |
| KR20150036578A (ko) | 2012-07-17 | 2015-04-07 | 더 리젠츠 오브 더 유니버시티 오브 미시간 | 백내장의 치료를 위한 알파-크리스탈린 응집의 억제제 |
| JP2015526515A (ja) | 2012-08-31 | 2015-09-10 | ボシュ・アンド・ロム・インコーポレイテッドＢａｕｓｃｈ ＆ Ｌｏｍｂ Ｉｎｃｏｒｐｏｒａｔｅｄ | オメガ３脂肪酸を有する眼用組成物 |
| AU2014360369B2 (en) * | 2013-12-05 | 2019-11-07 | University Of Miami | Compositions and methods for reducing intraocular pressure |
| KR20170048426A (ko) | 2014-08-22 | 2017-05-08 | 광저우 캉루이 바이오로지컬 파마슈티컬 테크놀로지 씨오., 엘티디. | 시각 장애를 치료하기 위한 조성물 및 방법 |
| WO2016029197A1 (en) * | 2014-08-22 | 2016-02-25 | Kang Zhang | Compositions and methods to treat and/or prevent vision disorders of the lens of the eye |
-
2016
- 2016-07-27 JP JP2018525507A patent/JP2018522070A/ja active Pending
- 2016-07-27 US US15/221,550 patent/US10398709B2/en active Active
- 2016-07-27 AU AU2016298951A patent/AU2016298951B2/en not_active Ceased
- 2016-07-27 CA CA2993196A patent/CA2993196A1/en not_active Abandoned
- 2016-07-27 EP EP16748430.2A patent/EP3328389A1/en not_active Withdrawn
- 2016-07-27 WO PCT/US2016/044337 patent/WO2017019808A1/en not_active Ceased
- 2016-07-27 CN CN201680055951.6A patent/CN108472303A/zh active Pending
-
2019
- 2019-07-24 US US16/521,035 patent/US20200016176A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018522070A5 (https=) | ||
| US11439590B2 (en) | Pharmaceutical ophthalmic compositions for intraocular administration and methods for fabricating thereof | |
| RU2632107C2 (ru) | Пероральная фармацевтическая композиция для профилактики или лечения синдрома "сухого глаза", содержащая ребамипид или его предшественник | |
| JP2001510170A (ja) | 光力学的治療法において血管新生抑制性ステロイド類を使用する方法・用途 | |
| CA3023243C (en) | Pharmaceutical ophthalmic compositions and methods for fabricating thereof | |
| CA3107707A1 (en) | Compositions and methods for treating the eye | |
| US20160243031A1 (en) | Pharmaceutical ophthalmic compositions and methods for fabricating thereof | |
| CN101175487B (zh) | 依布硒啉的制药用途 | |
| JP2025513090A (ja) | 眼疾患の治療のためのミコフェノール酸及び／又はベタメタゾンの医薬組成物 | |
| JP2018024677A (ja) | ラキニモドを使用する眼炎症性疾患の治療 | |
| US20190111045A1 (en) | Pharmaceutical ophthalmic compositions and methods for fabricating thereof | |
| WO2017179003A1 (en) | Topical compositions for ophthalmic and otic use | |
| JP2011144111A (ja) | 軸性近視の予防または治療剤 | |
| DK3229780T3 (en) | Ophthalmic composition for use in the treatment of dry eye syndrome | |
| CN110664829A (zh) | 京尼平苷在制备抗肺纤维化药物中的应用 | |
| US20220062255A1 (en) | Treatment of neurodegenerative eye disease using pridopidine | |
| JP2020514347A (ja) | チオトロピウムを有効成分として含有する近視予防、近視治療および／または近視進行抑制剤 | |
| CN110325214A (zh) | 用于预防和治疗神经元损伤的低剂量药物组合 | |
| JP2004256524A (ja) | ステロイド副作用抑制組成物 | |
| CN1239161C (zh) | 可用于治疗干眼疾病的类固醇 | |
| US20230158045A1 (en) | Pharmaceutical compositions of mycophenolic acid and/or betamethasone for the treatment of ocular disorders | |
| JP2019038783A (ja) | ドライアイの治療剤 | |
| CN117959316A (zh) | 一种包含恩格列净的药物组合物及其制备方法与制药用途 | |
| US20050038103A1 (en) | Uses of dorzolamide | |
| WO2006030753A1 (ja) | 角結膜障害治療剤 |